Phase I study of cisplatin analogue nedaplatin (254-S) and paclitaxel in patients with unresectable squamous cell carcinoma

British Journal of Cancer

Volumn 90, Issue 6, 2004, Pages 1125-1128

  Sekine, I ^a   Nokihara, H ^a   Horiike, A ^a   Yamamoto, N ^a   Kunitoh, H ^a   Ohe, Y ^a   Tamura, T ^a   Kodama, T ^a   Saijo, N ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Lung cancer; Nedaplatin; Paclitaxel; Squamous cell carcinoma

Indexed keywords

CISPLATIN DERIVATIVE; NEDAPLATIN; OXYGEN; PACLITAXEL; STEROID;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; CAUSE OF DEATH; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG FEVER; FEBRILE NEUTROPENIA; FEMALE; HEART ARRHYTHMIA; HUMAN; HYPONATREMIA; ILEUS; INFECTION; INFUSION; INTERSTITIAL PNEUMONIA; LEUKOPENIA; LIVER TOXICITY; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; OXYGEN THERAPY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; STEROID THERAPY; THROMBOCYTOPENIA; TREATMENT WITHDRAWAL;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PACLITAXEL; TREATMENT OUTCOME;

EID: 1942437542     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601700     Document Type: Article

References (21)

1. Ajani JA, Ilson DH, Daugherty K, Pazdur R, Lynch PM, Kelsen DP (1994) Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. j Natl Cancer Inst 86: 1086-1091
2. Akiyama Y, Ohe Y, Tamura T, Sawada M, Inoue A, Kusaba H, Yamamoto N, Sekine I, Kunitoh H, Kodama T, Saijo N (2001) A dose escalation study of paclitaxel and carboplatin in untreated Japanese patients with advanced non-small cell lung cancer. Jpn J Clin Oncol 31: 482-487
3. Armitage P, Berry G (1994) Survival analysis. In Statistical Methods in Medical Research, Armitage P, Berry G (eds) 3rd edn, pp 469-492. Oxford: Blackwell Scientific Publications
4. DeVita Jr VT, Hellman S, Rosenberg SA (2001) Cancer: Principles & Practice of Oncology, 6th edn Philadelphia: Lippincott Williams & Wilkins
5. Forastiere AA, Shank D, Neuberg D, Taylor IV SG, DeConti RC, Adams G (1998) Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial (PA390). Cancer 82: 2270-2274
6. Inuyama Y, Miyake H, Horiuchi M, Hayasaki K, Komiyama S, Ota K (1992) A late phase II clinical study of cis-diammine glycolato platinum, 254-S, for head and neck cancers. Gan To Kagaku Ryoho 19: 871-877 (Japanese)
7. JCOG Administrational Committee (1998) National Cancer Institute -Common Toxicity Criteria (NCI-CTC Version 2.0, Jan 30, 1998). Japanese edition by JCOG. Available at http://www.med.gunma-u.ac.jp/event/ CTCJ_v20.pdf
8. Kameyama Y, Okazaki N, Nakagawa M, Koshida H, Nakamura M, Gemba M (1990) Nephrotoxicity of a new platinum compound, 254-S, evaluated with rat kidney cortical slices. Toxicol Lett 52: 15-24
9. Kikuchi T, Daigo Y, Katagiri T, Tsunoda T, Okada K, Kakiuchi S, Zembutsu H, Furukawa Y, Kawamura M, Kobayashi K, Imai K, Nakamura Y (2003) Expression profiles of non-small cell lung cancers on cDNA microarrays: identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs. Oncogene 22: 2192-2205
10. Kobayashi H, Takemura Y, Miyachi H, Ogawa T (1991) Antitumor activities of new platinum compounds, DWA2114R, NK121 and 254-S, against human leukemia cells sensitive or resistant to cisplatin. Invest New Drugs 9: 313-319
11. Kurata T, Tamura T, Shinkai T, Ohe Y, Kunitoh H, Kodama T, Kakinuma R, Matsumoto T, Kubota K, Omatsu H, Nishiwaki Y, Saijo N (2001) Phase I and pharmacological study of paclitaxel given over 3 h with cisplatin for advanced non-small cell lung cancer. Jpn J Clin Oncol 31: 93-99
12. McGuire WP, Blessing JA, Moore D, Lentz SS, Photopulos G (1996) Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study. J Clin Oncol 14: 792-795
13. Noda K, Ikeda M, Yakushiji M, Nishimura H, Terashima Y, Sasaki H, Hata T, Kuramoto H, Tanaka K, Takahashi T, Hirabayashi K, Yamabe TH, Hatae M (1992) A phase II clinical study of cis-diammine glycolato platinum, 254-S, for cervical cancer of the uterus. Gan To Kagaku Ryoho 19: 885-892 (Japanese)
14. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649-655
15. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH, The Eastern Cooperative Oncology Group (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346: 92-98
16. Sekine I, Nishiwaki Y, Watanabe K, Yoneda S, Saijo N, Kikuchi K, Kawakami Y, Abe S, Fujita A, Shida A, Nukiwa T, Mori K, Saito R, Yoneda S, Kabe J, Hayashi I, Niitani K, Noda K, Kurita Y (1996) Phase II study of 3-h infusion of paclitaxel hi previously untreated non-small cell lung cancer. Clin Cancer Res 2: 941-945
17. Sekine I, Yamamoto N, Kunitoh H, Ohe Y, Tamura T, Kodama T, Saijo N (2002) Relationship between objective responses in phase I trials and potential efficacy of non-specific cytotoxic investigational new drugs. Ann Oncol 13: 1300-1306
18. Taguchi T, Wakui A, Nabeya K, Kurihara M, Isono K, Kakegawa T, Ota K (1992) A phase II clinical study of cis-diammine glycolato platinum, 254-S, for gastrointestinal cancers. 254-S Gastrointestinal Cancer Study Group. Gan To Kagaku Ryoho 19: 483-488 (Japanese)
19. Yamada H, Uchida N, Maekawa R, Yoshioka T (2001) Sequence-dependent antitumor efficacy of combination chemotherapy with nedaplatin, a newly developed platinum, and paclitaxel. Cancer Lett 172: 17-25
20. Yamamoto N, Tamura T, Kurata T (2000) Phase I and pharmacokinetic (PK) study of (Glycolate-0, 0′)-diammine platinum (II) (Nedaplatin: 254-S) in elderly patients with non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 19: 203a (abstr 792)
21. WHO (1979) Handbook for Reporting Results of Cancer Treatment, WHO Offset Publication No. 48 Geneva: World Health Organization